Last updated on January 2020

Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib Previously Treated With 2 or More TKIs


Brief description of study

The purpose of this pivotal study is to compare the efficacy of ABL001 with that of bosutinib in the treatment of patients with CML-CP having previously been treated with a minimum of two prior ATP-binding site TKIs.

Patients intolerant to the most recent TKI therapy must have BCR-ABL1 ratio > 0.1% IS at screening and patients failing their most recent TKI therapy must meet the definition of treatment failure as per the 2013 ELN guidelines.

Patients with documented treatment failure while on bosutinib treatment will have the option to switch to asciminib treatment within 96 weeks after the last patient has been randomized on study.

Clinical Study Identifier: NCT03106779

Find a site near you

Start Over

City of Hope

Duarte, CA United States
  Connect »

Mayo Clinic Arizona

Phoenix, AZ United States
  Connect »

Dana Farber Cancer Center

Boston, MA United States
  Connect »

Utah Huntsman Cancer Center

Salt Lake City, UT United States
  Connect »

Novartis Investigative Site

Capital Federal, Argentina
  Connect »

Novartis Investigative Site

Vandoeuvre les Nancy, France
  Connect »

Novartis Investigative Site

Seoul, Korea, Republic of
  Connect »

Novartis Investigative Site

Busan, Korea, Republic of
  Connect »

Novartis Investigative Site

Jeollanam-do, Korea, Republic of
  Connect »

Novartis Investigative Site

Moscow, Russian Federation
  Connect »

Novartis Investigative Site

Saint Petersburg, Russian Federation
  Connect »

Novartis Investigative Site

Hospitalet de LLobregat, Spain
  Connect »

Novartis Investigative Site

Merseyside, United Kingdom
  Connect »